This page follows insider dealings at Incannex Healthcare Inc. as filed with SEC (Form 4). 6 insiders have disclosed 6 filings since 25 October 2025.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
There has been no open-market purchase by an insider of Incannex Healthcare Inc. for at least a year.
Across the 5,808 companies tracked on its exchange, the median is 19 filings; at 6 filings, this issuer sits below that mark. In its latest annual report filed with the SEC (10-K, fiscal year ended 30 June 2026), the company reported net income of -19.3 m USD.
In the same market, recent insider purchases at GameStop Corp. and Heico Corp also feature in our signals. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Analysts rate Incannex Healthcare Inc. Strong Buy (bullish), based on 2 analysts. Average price target: US$18.67.
FY ended June 2024 · cache
12 of 12 declarations
Incannex Healthcare Inc. is a company focused on developing cannabis-based healthcare products. It emphasizes research and innovation in the field of medical treatments.
Purchases our model currently ranks for the recommendations list.
All recommendations| Fiscal year end | Revenue | Net income | Diluted EPS | Filing |
|---|---|---|---|---|
| Jun 2026 | n.d. | -19.3 m USD | -1.66 USD | 10-K |
| Jun 2025 | 86,000 USD | -46.9 m USD | -40.82 USD | 10-K |
| Jun 2024 | 12,000 USD | -18.5 m USD | -1.15 USD | 10-K |
| Jun 2021 | 1.9 m USD | -11.4 m USD | -1.16 USD | 20-F |
| Jun 2020 | 604,884 USD | -4.7 m USD | -0.57 USD | 20-F |
Amounts in USD, as filed (forms 10-K, 20-F or 40-F). Source: SEC EDGAR.